Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

Daily Top 10 COVID-19 papers


  Sexually Transmitted Diseases

  Free Subscription

Articles published in Oral Oncol

Retrieve available abstracts of 109 articles:
HTML format

Single Articles

    May 2020
  1. KYLMA AK, Jouhi L, Mohamed H, Randen-Brady R, et al
    In HPV-negative oropharyngeal squamous cell carcinoma, elevated toll-like receptor 2 immunoexpression may increase the risk of disease-specific mortality.
    Oral Oncol. 2020;107:104778.
    PubMed     Abstract available

    April 2020
  2. SCHROEDER L, Pring M, Ingarfield K, Pawlita M, et al
    HPV driven squamous cell head and neck cancer of unknown primary is likely to be HPV driven squamous cell oropharyngeal cancer.
    Oral Oncol. 2020;107:104721.
    PubMed     Abstract available

  3. MOLONY P, Werner R, Martin C, Callanan D, et al
    The role of tumour morphology in assigning HPV status in oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2020;105:104670.
    PubMed     Abstract available

    March 2020
  4. MAZUL AL, Colditz GA, Zevallos JP
    Factors associated with HPV testing in oropharyngeal cancer in the National Cancer Data Base from 2013 to 2015.
    Oral Oncol. 2020;104:104609.
    PubMed     Abstract available

    February 2020
  5. YIN X, Shan C, Wang J, Zhang H, et al
    Factors associated with the quality of life for hospitalized patients with HPV-associated oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2020;103:104590.
    PubMed     Abstract available

    December 2019
  6. ESKANDER A, Husain ZA
    HPV testing: A quality metric.
    Oral Oncol. 2019 Dec 30:104549. doi: 10.1016/j.oraloncology.2019.104549.

  7. YOUNG RJ, Bressel M, Porceddu S, Cernelc J, et al
    Validation and characterisation of prognostically significant PD-L1(+) immune cells in HPV+ oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2019;101:104516.
    PubMed     Abstract available

    November 2019
  8. STROBER W, Shishido S, Wood B, Lewis JS Jr, et al
    Two for the price of one: Prevalence, demographics and treatment implications of multiple HPV mediated Head and Neck Cancers.
    Oral Oncol. 2019;100:104475.
    PubMed     Abstract available

  9. LU DJ, Luu M, Nguyen AT, Scher KS, et al
    Survival outcomes with concomitant chemoradiotherapy in older adults with oropharyngeal carcinoma in an era of increasing human papillomavirus (HPV) prevalence.
    Oral Oncol. 2019;99:104472.
    PubMed     Abstract available

    October 2019
  10. MICCIO JA, Verma V, Kelly J, Kann BH, et al
    Impact of contralateral lymph nodal involvement and extranodal extension on survival of surgically managed HPV-positive oropharyngeal cancer staged with the AJCC eighth edition.
    Oral Oncol. 2019;99:104447.
    PubMed     Abstract available

    September 2019
  11. SANFORD NN, Hwang WL, Pike LRG, Lam AC, et al
    Trimodality therapy for HPV-positive oropharyngeal cancer: A population-based study: Trimodality therapy for HPV+OPC.
    Oral Oncol. 2019;98:28-34.
    PubMed     Abstract available

  12. GRONHOJ C, Kronberg Jakobsen K, Kjaer E, Friborg J, et al
    Comorbidity in HPV+ and HPV- oropharyngeal cancer patients: A population-based, case-control study.
    Oral Oncol. 2019;96:1-6.
    PubMed     Abstract available

    August 2019
  13. IGANEJ S, Beard BW, Chen J, Buchschacher GL Jr, et al
    Triweekly carboplatin as a potential de-intensification agent in concurrent chemoradiation for early-stage HPV-associated oropharyngeal cancer.
    Oral Oncol. 2019;97:18-22.
    PubMed     Abstract available

  14. BHATTASALI O, Ryoo JJ, Thompson LDR, Abdalla IA, et al
    Impact of chemotherapy regimen on treatment outcomes in patients with HPV-associated oropharyngeal cancer with T4 disease treated with definitive concurrent chemoradiation.
    Oral Oncol. 2019;95:74-78.
    PubMed     Abstract available

  15. LEONARD BC, Lee ED, Bhola NE, Li H, et al
    ATR inhibition sensitizes HPV(-) and HPV(+) head and neck squamous cell carcinoma to cisplatin.
    Oral Oncol. 2019;95:35-42.
    PubMed     Abstract available

  16. MISIUKIEWICZ K, Gupta V, Miles BA, Bakst R, et al
    Standard of care vs reduced-dose chemoradiation after induction chemotherapy in HPV+ oropharyngeal carcinoma patients: The Quarterback trial.
    Oral Oncol. 2019;95:170-177.
    PubMed     Abstract available

  17. HANNA GJ, Lau CJ, Mahmood U, Supplee JG, et al
    Salivary HPV DNA informs locoregional disease status in advanced HPV-associated oropharyngeal cancer.
    Oral Oncol. 2019;95:120-126.
    PubMed     Abstract available

    July 2019
  18. JAYARAJ R, Kumarasamy C, Madhav MR, Shetty S, et al
    Clinical validation of the Salivary HPV DNA assessment and its link to the locoregional disease burden in advanced HPV associated oropharyngeal cancer.
    Oral Oncol. 2019 Jul 30. pii: S1368-8375(19)30264.

    June 2019
  19. IQBAL MS, Kovarik J, Kelly C
    Limiting radiotherapy field to ipsilateral side only in unresected lateralised HPV positive N2b squamous cell carcinoma of the tonsil.
    Oral Oncol. 2019 Jun 12. pii: S1368-8375(19)30203.

  20. MCMULLEN CP, Garneau J, Weimar E, Ali S, et al
    Occult contralateral nodal disease in oropharyngeal squamous cell carcinoma patients undergoing primary TORS with bilateral neck dissection.
    Oral Oncol. 2019;93:96-100.
    PubMed     Abstract available

    May 2019
  21. MARTIN-GOMEZ L, Fulp WJ, Schell MJ, Sirak B, et al
    Oral gargle-tumor biopsy human papillomavirus (HPV) agreement and associated factors among oropharyngeal squamous cell carcinoma (OPSCC) cases.
    Oral Oncol. 2019;92:85-91.
    PubMed     Abstract available

  22. BURR AR, Harari PM, Ko HC, Bruce JY, et al
    Reducing radiotherapy target volume expansion for patients with HPV-associated oropharyngeal cancer.
    Oral Oncol. 2019;92:52-56.
    PubMed     Abstract available

    April 2019
  23. DE FELICE F, Polimeni A, Tombolini V
    Human papillomavirus (HPV) vaccine and HPV-related head and neck cancer: What's next?
    Oral Oncol. 2019 Apr 4. pii: S1368-8375(19)30101.

    March 2019
  24. JAYARAJ R, Kumarasamy C, Royam MM, Sabarimurugan S, et al
    Prognostic implications of pathologic lymph nodes in HPV-positive oropharyngeal cancers: Clinical validity and strategies for routine clinical practice.
    Oral Oncol. 2019 Mar 8. pii: S1368-8375(19)30074.

  25. EL-SALEM F, Mansour M, Gitman M, Miles BA, et al
    Real-time PCR HPV genotyping in fine needle aspirations of metastatic head and neck squamous cell carcinoma: Exposing the limitations of conventional p16 immunostaining.
    Oral Oncol. 2019;90:74-79.
    PubMed     Abstract available

  26. GHANIZADA M, Jakobsen KK, Gronhoj C, von Buchwald C, et al
    The effects of checkpoint inhibition on head and neck squamous cell carcinoma: A systematic review.
    Oral Oncol. 2019;90:67-73.
    PubMed     Abstract available

  27. FRIEDMAN J, Padget M, Lee J, Schlom J, et al
    Direct and antibody-dependent cell-mediated cytotoxicity of head and neck squamous cell carcinoma cells by high-affinity natural killer cells.
    Oral Oncol. 2019;90:38-44.
    PubMed     Abstract available

    February 2019
  28. EL ASMAR M, Tsai HL, Fakhry C, Maroun CA, et al
    The prognostic impact of pathologic lymph nodes in HPV-positive oropharyngeal cancers.
    Oral Oncol. 2019;89:23-29.
    PubMed     Abstract available

  29. ROSS RB, Juloori A, Varra V, Ward MC, et al
    Five-year outcomes of sparing level IB in node-positive, human papillomavirus-associated oropharyngeal carcinoma: A safety and efficacy analysis.
    Oral Oncol. 2019;89:66-71.
    PubMed     Abstract available

  30. MESHMAN J, Velez MA, Wang PC, Abemayor E, et al
    Immunologic mediators of outcome for irradiated oropharyngeal carcinoma based on human papillomavirus status.
    Oral Oncol. 2019;89:121-126.
    PubMed     Abstract available

    January 2019
  31. PAOLINI F, Bonomo C, Terrenato I, Pennetti A, et al
    Beta human papillomaviruses in middle ear squamous cell carcinoma.
    Oral Oncol. 2019 Jan 18. pii: S1368-8375(19)30004.

  32. ALTAMURA G, Borzacchiello G
    HPV related head and neck squamous cell carcinoma: New evidences for an emerging spontaneous animal model.
    Oral Oncol. 2019;88:84.

  33. LIU HY, Milne R, Lock G, Panizza BJ, et al
    Utility of a repeat PET/CT scan in HPV-associated Oropharyngeal Cancer following incomplete nodal response from (chemo)radiotherapy.
    Oral Oncol. 2019;88:153-159.
    PubMed     Abstract available

    December 2018
  34. JAYARAJ R, Kumarasamy C
    Comment on, "Survival for HPV-positive oropharyngeal squamous cell carcinoma with surgical versus non-surgical treatment approach: A systematic review and meta-analysis".
    Oral Oncol. 2018 Dec 19. pii: S1368-8375(18)30483.

    November 2018
  35. PIKE LRG, Hwang WL, Royce TJ, Sanford NN, et al
    HPV status predicts for improved survival following chemotherapy in metastatic squamous cell carcinoma of the oropharynx.
    Oral Oncol. 2018;86:69-74.
    PubMed     Abstract available

  36. SATHASIVAM HP, Bhatia R, Bradley P, Robson A, et al
    Concurrent HPV-related oropharyngeal carcinoma in four couples.
    Oral Oncol. 2018;86:33-37.
    PubMed     Abstract available

  37. CANNON RB, Houlton JJ, Patel S, Raju S, et al
    Patterns of cervical node positivity, regional failure rates, and fistula rates for HPV+ oropharyngeal squamous cell carcinoma treated with transoral robotic surgery (TORS).
    Oral Oncol. 2018;86:296-300.
    PubMed     Abstract available

  38. HUANG SH, Hahn E, Tsang RK, Chen ZJ, et al
    The interplay of IMRT and transoral surgery in HPV-mediated oropharyngeal cancer: Getting the balance right.
    Oral Oncol. 2018;86:171-180.
    PubMed     Abstract available

  39. SINHA P, Karadaghy OA, Doering MM, Tuuli MG, et al
    Survival for HPV-positive oropharyngeal squamous cell carcinoma with surgical versus non-surgical treatment approach: A systematic review and meta-analysis.
    Oral Oncol. 2018;86:121-131.
    PubMed     Abstract available

  40. SHAIKH MH, Idris A, Johnson NW, Fallaha S, et al
    Aurora kinases are a novel therapeutic target for HPV-positive head and neck cancers.
    Oral Oncol. 2018;86:105-112.
    PubMed     Abstract available

  41. EVANS M, Beasley M
    Target delineation for postoperative treatment of head and neck cancer.
    Oral Oncol. 2018;86:288-295.
    PubMed     Abstract available

    October 2018
  42. AMBATIPUDI S, Langdon R, Richmond RC, Suderman M, et al
    DNA methylation derived systemic inflammation indices are associated with head and neck cancer development and survival.
    Oral Oncol. 2018;85:87-94.
    PubMed     Abstract available

  43. LEE DJ, Eun YG, Rho YS, Kim EH, et al
    Three distinct genomic subtypes of head and neck squamous cell carcinoma associated with clinical outcomes.
    Oral Oncol. 2018;85:44-51.
    PubMed     Abstract available

    September 2018
  44. GELTZEILER M, Bertolet M, Albergotti W, Gleysteen J, et al
    Staging HPV-related oropharyngeal cancer: Validation of AJCC-8 in a surgical cohort.
    Oral Oncol. 2018;84:82-87.
    PubMed     Abstract available

  45. CHEN MM, Colevas AD, Megwalu U, Divi V, et al
    Survival benefit of post-operative chemotherapy for intermediate-risk advanced stage head and neck cancer differs with patient age.
    Oral Oncol. 2018;84:71-75.
    PubMed     Abstract available

    August 2018
  46. LECHNER M, Chakravarthy AR, Walter V, Masterson L, et al
    Frequent HPV-independent p16/INK4A overexpression in head and neck cancer.
    Oral Oncol. 2018;83:32-37.
    PubMed     Abstract available

  47. GRONHOJ C, Jakobsen KK, Jensen DH, Rasmussen J, et al
    Pattern of and survival following loco-regional and distant recurrence in patients with HPV+ and HPV- oropharyngeal squamous cell carcinoma: A population-based study.
    Oral Oncol. 2018;83:127-133.
    PubMed     Abstract available

    July 2018
  48. PASALIC D, Funk RK, Garcia JJ, Price DL, et al
    Magnitude of benefit for adjuvant radiotherapy following minimally invasive surgery in intermediate to high risk HPV-positive oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2018;82:181-186.
    PubMed     Abstract available

  49. HOBELMANN KC, Topf MC, Bar-Ad V, Luginbuhl AJ, et al
    AJCC-8ed nodal staging does not predict outcomes in surgically managed HPV-associated oropharyngeal cancer.
    Oral Oncol. 2018;82:138-143.
    PubMed     Abstract available

  50. MIRGHANI H, Leroy C, Chekourry Y, Casiraghi O, et al
    Smoking impact on HPV driven head and neck cancer's oncological outcomes?
    Oral Oncol. 2018;82:131-137.
    PubMed     Abstract available

  51. MIRGHANI H, Lang Kuhs KA, Waterboer T
    Biomarkers for early identification of recurrences in HPV-driven oropharyngeal cancer.
    Oral Oncol. 2018;82:108-114.
    PubMed     Abstract available

    June 2018
  52. FERRIS RL, Blumenschein G Jr, Fayette J, Guigay J, et al
    Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression.
    Oral Oncol. 2018;81:45-51.
    PubMed     Abstract available

  53. OSAZUWA-PETERS N, Arnold LD, Loux TM, Varvares MA, et al
    Factors associated with increased risk of suicide among survivors of head and neck cancer: A population-based analysis.
    Oral Oncol. 2018;81:29-34.
    PubMed     Abstract available

    May 2018
  54. NULTON TJ, Kim NK, DiNardo LJ, Morgan IM, et al
    Patients with integrated HPV16 in head and neck cancer show poor survival.
    Oral Oncol. 2018;80:52-55.
    PubMed     Abstract available

    April 2018
  55. VANGELOV B, Kotevski DP, Williams JR, Smee RI, et al
    The impact of HPV status on weight loss and feeding tube use in oropharyngeal carcinoma.
    Oral Oncol. 2018;79:33-39.
    PubMed     Abstract available

    March 2018
  56. GOUW ZAR, Paul de Boer J, Navran A, van den Brekel MWM, et al
    Baseline peripheral blood leukocytosis: Biological marker predicts outcome in oropharyngeal cancer, regardless of HPV-status.
    Oral Oncol. 2018;78:200-206.
    PubMed     Abstract available

  57. LU S, Concha-Benavente F, Shayan G, Srivastava RM, et al
    STING activation enhances cetuximab-mediated NK cell activation and DC maturation and correlates with HPV(+) status in head and neck cancer.
    Oral Oncol. 2018;78:186-193.
    PubMed     Abstract available

  58. CHANNIR HI, Kiss K, Rubek N, Andersen J, et al
    Comparison of clinical, radiological and morphological features including the distribution of HPV E6/E7 oncogenes in resection specimens of oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2018;78:163-170.
    PubMed     Abstract available

  59. MENA M, Taberna M, Tous S, Marquez S, et al
    Double positivity for HPV-DNA/p16(ink4a) is the biomarker with strongest diagnostic accuracy and prognostic value for human papillomavirus related oropharyngeal cancer patients.
    Oral Oncol. 2018;78:137-144.
    PubMed     Abstract available

  60. WANG K, Wong TZ, Amdur RJ, Mendenhall WM, et al
    Pitfalls of post-treatment PET after de-intensified chemoradiotherapy for HPV-associated oropharynx cancer: Secondary analysis of a phase 2 trial.
    Oral Oncol. 2018;78:108-113.
    PubMed     Abstract available

    February 2018
  61. GIPSON BJ, Robbins HA, Fakhry C, D'Souza G, et al
    Sensitivity and specificity of oral HPV detection for HPV-positive head and neck cancer.
    Oral Oncol. 2018;77:52-56.
    PubMed     Abstract available

  62. MAJERCAKOVA K, Valero C, Lopez M, Garcia J, et al
    Postoperative staging of the neck dissection using extracapsular spread and lymph node ratio as prognostic factors in HPV-negative head and neck squamous cell carcinoma patients.
    Oral Oncol. 2018;77:37-42.
    PubMed     Abstract available

  63. PAI SI, Jack Lee J, Carey TE, Westra WH, et al
    HLA class I antigen processing machinery (APM) component expression and PD-1:PD-L1 pathway activation in HIV-infected head and neck cancers.
    Oral Oncol. 2018;77:92-97.
    PubMed     Abstract available

  64. VAN DEN BOVENKAMP K, Dorgelo B, Noordhuis MG, van der Laan BFAM, et al
    Viable tumor in salvage neck dissections in head and neck cancer: Relation with initial treatment, change of lymph node size and human papillomavirus.
    Oral Oncol. 2018;77:131-136.
    PubMed     Abstract available

    January 2018
  65. JANSEN L, Buttmann-Schweiger N, Listl S, Ressing M, et al
    Differences in incidence and survival of oral cavity and pharyngeal cancers between Germany and the United States depend on the HPV-association of the cancer site.
    Oral Oncol. 2018;76:8-15.
    PubMed     Abstract available

    October 2017
  66. UPADHYAY P, Gardi N, Desai S, Chandrani P, et al
    Genomic characterization of tobacco/nut chewing HPV-negative early stage tongue tumors identify MMP10 asa candidate to predict metastases.
    Oral Oncol. 2017;73:56-64.
    PubMed     Abstract available

  67. SHARMA SJ, Wittekindt C, Knuth J, Steiner D, et al
    Intraindividual homogeneity of 18F-FDG PET/CT parameters in HPV-positive OPSCC.
    Oral Oncol. 2017;73:166-171.
    PubMed     Abstract available

  68. ZHAN KY, Eskander A, Kang SY, Old MO, et al
    Appraisal of the AJCC 8th edition pathologic staging modifications for HPV-positive oropharyngeal cancer, a study of the National Cancer Data Base.
    Oral Oncol. 2017;73:152-159.
    PubMed     Abstract available

    September 2017
  69. DONA MG, Rollo F, Pichi B, Spriano G, et al
    Evaluation of the Xpert(R) HPV assay in the detection of Human Papillomavirus in formalin-fixed paraffin-embedded oropharyngeal carcinomas.
    Oral Oncol. 2017;72:117-122.
    PubMed     Abstract available

  70. ADKINS D, Ley J, Oppelt P, Wildes TM, et al
    nab-Paclitaxel-based induction chemotherapy with or without cetuximab for locally advanced head and neck squamous cell carcinoma.
    Oral Oncol. 2017;72:26-31.
    PubMed     Abstract available

    August 2017
  71. OU D, Blanchard P, Rosellini S, Levy A, et al
    Predictive and prognostic value of CT based radiomics signature in locally advanced head and neck cancers patients treated with concurrent chemoradiotherapy or bioradiotherapy and its added value to Human Papillomavirus status.
    Oral Oncol. 2017;71:150-155.
    PubMed     Abstract available

    July 2017
  72. BROGLIE MA, Jochum W, Michel A, Waterboer T, et al
    Evaluation of type-specific antibodies to high risk-human papillomavirus (HPV) proteins in patients with oropharyngeal cancer.
    Oral Oncol. 2017;70:43-50.
    PubMed     Abstract available

    June 2017
  73. DABAS S, Gupta K, Ranjan R, Sharma AK, et al
    Oncological outcome following de-intensification of treatment for stage I and II HPV negative oropharyngeal cancers with transoral robotic surgery (TORS): A prospective trial.
    Oral Oncol. 2017;69:80-83.
    PubMed     Abstract available

  74. LAPRISE C, Madathil SA, Schlecht NF, Castonguay G, et al
    Human papillomavirus genotypes and risk of head and neck cancers: Results from the HeNCe Life case-control study.
    Oral Oncol. 2017;69:56-61.
    PubMed     Abstract available

    May 2017
  75. DODD RH, Forster AS, Waller J, Marlow LAV, et al
    Discussing HPV with oropharyngeal cancer patients: A cross-sectional survey of attitudes in health professionals.
    Oral Oncol. 2017;68:67-73.
    PubMed     Abstract available

  76. SHAIKH MH, Clarke DTW, Johnson NW, McMillan NAJ, et al
    Can gene editing and silencing technologies play a role in the treatment of head and neck cancer?
    Oral Oncol. 2017;68:9-19.
    PubMed     Abstract available

    April 2017
  77. ZHANG Y, Waterboer T, Haddad RI, Miles BA, et al
    Human papillomavirus (HPV) 16 antibodies at diagnosis of HPV-related oropharyngeal cancer and antibody trajectories after treatment.
    Oral Oncol. 2017;67:77-82.
    PubMed     Abstract available

  78. LACAU ST GUILY J, Rousseau A, Baujat B, Perie S, et al
    Oropharyngeal cancer prognosis by tumour HPV status in France: The multicentric Papillophar study.
    Oral Oncol. 2017;67:29-36.
    PubMed     Abstract available

  79. PEREZ CA, Wu X, Amsbaugh MJ, Gosain R, et al
    High-dose versus weekly cisplatin definitive chemoradiotherapy for HPV-related oropharyngeal squamous cell carcinoma of the head and neck.
    Oral Oncol. 2017;67:24-28.
    PubMed     Abstract available

  80. MIRGHANI H, Sturgis EM, Auperin A, Monsonego J, et al
    Is there an increased risk of cancer among spouses of patients with an HPV-related cancer: A systematic review.
    Oral Oncol. 2017;67:138-145.
    PubMed     Abstract available

  81. TOTA JE, Anderson WF, Coffey C, Califano J, et al
    Rising incidence of oral tongue cancer among white men and women in the United States, 1973-2012.
    Oral Oncol. 2017;67:146-152.
    PubMed     Abstract available

  82. KOFLER B, Borena W, Manzl C, Dudas J, et al
    Sensitivity of tumor surface brushings to detect human papilloma virus DNA in head and neck cancer.
    Oral Oncol. 2017;67:103-108.
    PubMed     Abstract available

    March 2017
  83. PORCEDDU SV, Milne R, Brown E, Bernard A, et al
    Validation of the ICON-S staging for HPV-associated oropharyngeal carcinoma using a pre-defined treatment policy.
    Oral Oncol. 2017;66:81-86.
    PubMed     Abstract available

    February 2017
  84. GELTZEILER M, Clayburgh D, Gleysteen J, Gross ND, et al
    Predictors of extracapsular extension in HPV-associated oropharyngeal cancer treated surgically.
    Oral Oncol. 2017;65:89-93.
    PubMed     Abstract available

  85. MASSA ST, Osazuwa-Peters N, Christopher KM, Arnold LD, et al
    Competing causes of death in the head and neck cancer population.
    Oral Oncol. 2017;65:8-15.
    PubMed     Abstract available

    January 2017
  86. MARTEL M, Alemany L, Taberna M, Mena M, et al
    The role of HPV on the risk of second primary neoplasia in patients with oropharyngeal carcinoma.
    Oral Oncol. 2017;64:37-43.
    PubMed     Abstract available

    December 2016
  87. D'SOUZA G, Anantharaman D, Gheit T, Abedi-Ardekani B, et al
    Corrigendum to 'Effect of HPV on head and neck cancer patient survival, by region and tumor site: A comparison of 1362 cases across three continents' [Oral Oncol. 62 (2016) 20-27].
    Oral Oncol. 2016 Dec 30. pii: S1368-8375(16)30270.

  88. JEANNON JP, Tanaka A, Thavaraj S, Guerrero-Urbano T, et al
    ATR gene mutations in HPV negative oropharyngeal cancer.
    Oral Oncol. 2016 Dec 22. pii: S1368-8375(16)30244.

  89. CHERA B, Wang K, Monroe A, Galloway T, et al
    Truth or myth: Definitive chemoradiotherapy doesn't work for HPV/p16 negative oropharyngeal squamous cell carcinoma?
    Oral Oncol. 2016 Dec 16. pii: S1368-8375(16)30234.

  90. INGLEHART RC, Taberna M, Pickard RK, Hoff M, et al
    HPV knowledge gaps and information seeking by oral cancer patients.
    Oral Oncol. 2016;63:23-29.
    PubMed     Abstract available

  91. FERNANDEZ-MATEOS J, Seijas-Tamayo R, Mesia R, Taberna M, et al
    Epidermal growth factor receptor (EGFR) pathway polymorphisms as predictive markers of cetuximab toxicity in locally advanced head and neck squamous cell carcinoma (HNSCC) in a Spanish population.
    Oral Oncol. 2016;63:38-43.
    PubMed     Abstract available

    November 2016
  92. D'SOUZA G, Anantharaman D, Gheit T, Abedi-Ardekani B, et al
    Effect of HPV on head and neck cancer patient survival, by region and tumor site: A comparison of 1362 cases across three continents.
    Oral Oncol. 2016;62:20-27.
    PubMed     Abstract available

  93. HAUGHEY BH, Sinha P, Kallogjeri D, Goldberg RL, et al
    Pathology-based staging for HPV-positive squamous carcinoma of the oropharynx.
    Oral Oncol. 2016;62:11-19.
    PubMed     Abstract available

  94. MIRGHANI H, Casiraghi O, Guerlain J, Amen F, et al
    Diagnosis of HPV driven oropharyngeal cancers: Comparing p16 based algorithms with the RNAscope HPV-test.
    Oral Oncol. 2016;62:101-108.
    PubMed     Abstract available

  95. KINDT N, Descamps G, Seminerio I, Bellier J, et al
    Langerhans cell number is a strong and independent prognostic factor for head and neck squamous cell carcinomas.
    Oral Oncol. 2016;62:1-10.
    PubMed     Abstract available

    October 2016
  96. WIRTH LJ, Dakhil S, Kornek G, Axelrod R, et al
    PARTNER: An open-label, randomized, phase 2 study of docetaxel/cisplatin chemotherapy with or without panitumumab as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck.
    Oral Oncol. 2016;61:31-40.
    PubMed     Abstract available

  97. LOW GM, Thylur DS, N Yamamoto V, Sinha UK, et al
    The effect of human papillomavirus on DNA repair in head and neck squamous cell carcinoma.
    Oral Oncol. 2016;61:27-30.
    PubMed     Abstract available

    August 2016
  98. OU D, Levy A, Blanchard P, Nguyen F, et al
    Concurrent chemoradiotherapy with cisplatin or cetuximab for locally advanced head and neck squamous cell carcinomas: Does human papilloma virus play a role?
    Oral Oncol. 2016;59:50-7.
    PubMed     Abstract available

    July 2016
  99. WANG K, Amdur RJ, Mendenhall WM, Green R, et al
    Impact of post-chemoradiotherapy superselective/selective neck dissection on patient reported quality of life.
    Oral Oncol. 2016;58:21-6.
    PubMed     Abstract available

    May 2016
  100. FENG Y, Li Y, Zhang Y, Zheng H, et al
    Association of genetic variants with tumor HPV16 status and survival in squamous cell carcinoma of the oropharynx.
    Oral Oncol. 2016;56:78-83.
    PubMed     Abstract available

  101. ZAFEREO ME, Xu L, Dahlstrom KR, Viamonte CA, et al
    Squamous cell carcinoma of the oral cavity often overexpresses p16 but is rarely driven by human papillomavirus.
    Oral Oncol. 2016;56:47-53.
    PubMed     Abstract available

  102. LAROCCA CJ, Han J, Salzwedel AO, Davydova J, et al
    Oncolytic adenoviruses targeted to Human Papilloma Virus-positive head and neck squamous cell carcinomas.
    Oral Oncol. 2016;56:25-31.
    PubMed     Abstract available

  103. AMINI A, Jasem J, Jones BL, Robin TP, et al
    Predictors of overall survival in human papillomavirus-associated oropharyngeal cancer using the National Cancer Data Base.
    Oral Oncol. 2016;56:1-7.
    PubMed     Abstract available

    April 2016
  104. KANG H, Kwon M, Park JJ, Kim JP, et al
    Clinical implications of human papilloma virus and other biologic markers in nasopharyngeal cancer.
    Oral Oncol. 2016;55:e7-e10.

    March 2016
  105. SEDGHIZADEH PP, Billington WD, Paxton D, Ebeed R, et al
    Is p16-positive oropharyngeal squamous cell carcinoma associated with favorable prognosis? A systematic review and meta-analysis.
    Oral Oncol. 2016;54:15-27.
    PubMed     Abstract available

  106. SHER DJ, Schwartz DL, Nedzi L, Khan S, et al
    Comparative effectiveness of induction chemotherapy for oropharyngeal squamous cell carcinoma: A population-based analysis.
    Oral Oncol. 2016;54:58-67.
    PubMed     Abstract available

  107. OZRETIC L, Wagner S, Huebbers CU, Gattenlohner S, et al
    FGFR1 amplification and co-overexpression of c-MYC in oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2016;54:e7-9.

    January 2016
  108. MAZUREK AM, Rutkowski T, Fiszer-Kierzkowska A, Malusecka E, et al
    Assessment of the total cfDNA and HPV16/18 detection in plasma samples of head and neck squamous cell carcinoma patients.
    Oral Oncol. 2016 Jan 11. pii: S1368-8375(15)00428.
    PubMed     Abstract available

  109. GUO T, Rettig E, Fakhry C
    Understanding the impact of survival and human papillomavirus tumor status on timing of recurrence in oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2016;52:97-103.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Sexually Transmitted Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.